Charity Wayua et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 56(1), 113-119 (2014-12-17)
Tumor-specific targeting ligands were recently exploited to deliver both imaging and therapeutic agents selectively to cancer tissues in vivo. Because the cholecystokinin 2 receptor (CCK2R) is overexpressed in various human cancers (e.g., lung, medullary thyroid, pancreatic, colon, and gastrointestinal stromal